Avapritinib(Ayvakit)

Avapritinib produced by Lucius Pharmaceuticals, as a precision-targeted therapeutic drug, has demonstrated favorable clinical value in addressing tumors and mast cell diseases caused by specific gene mutations, providing a treatment option for the corresponding patient population.

Avapritinib manufactured by Lucius Pharmaceuticals, with its highly effective targeted therapeutic effect and reasonable pricing strategy, offers patients a cost-effective treatment choice.

The following is an overview of the key information about avapritinib:

Active Ingredient

The main active ingredient is avapritinib, a kinase inhibitor.

Target Population

It is indicated for adult patients with PDGFRA-mutated GIST, AdvSM, or ISM.

Dosage and Administration

The recommended dose varies by indication: 300 mg once daily for GIST, 200 mg once daily for AdvSM, and 25 mg once daily for ISM. All doses should be taken on an empty stomach. Reference article: Dosage and Administration of Avapritinib

Medication Use in Special Populations

Dose adjustment is required for patients with severe hepatic impairment. It is not recommended for AdvSM or ISM patients with a platelet count below 50×10⁹/L.

Storage

The medication should be stored at room temperature (20°C–25°C), protected from moisture and light.

Pharmacokinetics

Pharmacokinetic data show that its time to reach peak concentration is approximately 2–4 hours, and it has a long half-life, making it suitable for once-daily administration.

FDA，2024.11